{"id":"W4290719500","doi":"10.1200/po.22.00165","title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","year":2022,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Cancer; Breast cancer; Targeted therapy; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Gefitinib; Estrogen receptor; Epidermal growth factor receptor; Phases of clinical research; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003858922,0.0002209873,0.0006045207,0.0003320521,0.0005475332,0.00001628175,0.0001860478,0.00005958187,0.0003793452],"category_scores_gemma":[0.0004805682,0.0001396287,0.0001099364,0.0008610047,0.00008362003,0.0001685978,0.00007172349,0.0002545378,4.084943e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007224954,"about_ca_system_score_gemma":0.0007241446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002984095,"about_ca_topic_score_gemma":0.001908164,"domain_scores_codex":[0.997366,0.0003221096,0.0008134479,0.0005437156,0.0007386238,0.0002160826],"domain_scores_gemma":[0.9973691,0.0009861643,0.0007447933,0.0002576744,0.0005702105,0.00007206623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3935976,0.05869985,0.4062887,0.00002755945,0.007869871,0.0000337627,0.03077204,0.01366559,0.00172313,0.0001289994,0.0005386419,0.08665425],"study_design_scores_gemma":[0.5274307,0.07624798,0.3862477,0.00006789016,0.0008055461,0.000001103831,0.002134494,0.000269627,0.0009956914,0.00009426678,0.005402653,0.0003024043],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978152,0.000015344,0.0001633437,0.0006288624,0.0001224397,0.01963357,0.001098862,0.00002166303,0.0001639025],"genre_scores_gemma":[0.9745991,0.000001911023,0.001103614,0.0002452222,0.0001145404,0.02268407,0.001164933,0.00002823687,0.0000584291],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1338331,"threshold_uncertainty_score":0.5693893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06288459229454123,"score_gpt":0.4389085319902534,"score_spread":0.3760239396957122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}